Table 4 |
|||
|
Multivariate analysis of the first major infection (dependent variable) and clinical and therapy variables (independent variables) |
|||
| Variables |
Odds ratio |
95% confidence interval |
p value |
|
|
|||
| Disease duration |
1.18 |
1.07–1.31 |
0.001 |
| Previous SLE glomerulonephritis |
3.92 |
0.71–21.56 |
0.116 |
| Hydroxychloroquinea |
0.05 |
0.01–0.23 |
0.0001 |
| Intravenous methylprednisolonea |
2.18 |
0.36–13.13 |
0.392 |
| Intravenous cyclophosphamidea |
0.35 |
0.03–3.87 |
0.390 |
|
|
|||
|
aUse within the last 3 months before the first major infection or previous use since lupus diagnosis if no major infection. SLE, systemic lupus erythematosus. |
|||
|
Bultink et al. Arthritis Research & Therapy 2006 8:R183 doi:10.1186/ar2095 |
|||
